Epilepsy is known to comorbid with
Alzheimer's disease. It can promote
cognitive decline, and eventually worsen their prognosis and mortality. It is sometimes difficult to find a suitable
drug because of the adverse effects.
Perampanel has a unique mechanism of action that antagonizes α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid type
glutamate receptor. Here, we report a case of severe
dementia due to
Alzheimer's disease with
intractable epilepsy, which
perampanel effected for controlling
seizures with less adverse effects. The subject is an 89-year-old Japanese woman with severe
dementia due to
Alzheimer's disease and intractable
myoclonic epilepsy. She also had psychiatric symptoms, such as
circadian rhythm disorder and irritability.
Valproic acid,
lacosamide, or
carbamazepine were prescribed, but none of them was effective. Shortly after
perampanel started, however,
myoclonus and these psychiatric symptoms improved. Moreover, it did not cause any obvious adverse effects, which made it possible to continue
perampanel until the end of her life.
Perampanel may be useful for controlling
intractable epilepsy accompanied by
Alzheimer's disease. It may also improve psychiatric symptoms with less adverse effect. Accumulation of studies is necessary to evaluate the effectiveness of
perampanel on the
epilepsy of
Alzheimer's disease patients and further understand that mechanism.